Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-21-000219
Filing Date
2021-01-04
Accepted
2021-01-04 20:00:08
Documents
2
Period of Report
2020-12-30

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 9424
2 EX-24 DOCUMENT attachment1.htm EX-24 4701
  Complete submission text file 0000899243-21-000219.txt   15508
Mailing Address C/O AVALANCHE BIOTECHNOLOGIES, INC. 1035 O'BRIEN DRIVE, SUITE A MENLO PARK CA 94025
Business Address
Hull Hans (Reporting) CIK: 0001614876 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39303 | Film No.: 21503534

Mailing Address 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080 650-481-6770
PLIANT THERAPEUTICS, INC. (Issuer) CIK: 0001746473 (see all company filings)

EIN.: 474272481 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations